Back

Serological Cytokine and chemokine profile in pregnant women with COVID19 in Mexico City

Cerbulo-Vazquez, A.; Zavala-Barrios, B.; Briones-Garduno, J. C.; Guerrero-Avendano, G. M. L.; Arriaga-Pizano, L.; Ferat-Osorio, E.; Cabrera-Rivera, G. L.; Miranda-Cruz, P.; Garcia de la Rosa, M. T.; Prieto-Chavez, J. L.; Rivero-Arredondo, V.; Madera-Sandoval, R.; Cruz-Cruz, A.; Salazar-Rios, E.; Serrano-Molina, D.; De Lira-Barraza, R.; Villanueva-Compean, A. H.; Esquivel-Pineda, A.; Ramirez-Montes de Oca, R.; Flores-Padilla, G.; Lopez-Macias, C.

2020-07-17 infectious diseases
10.1101/2020.07.14.20153585 medRxiv
Show abstract

On January 30th, 2020, the WHO declared the outbreak of COVID19, a disease due to the new coronavirus called SARS-CoV-2. Certain comorbidities, symptoms and signs are characteristic of COVID19 in the general population and in pregnant women. However, pregnant women are considered as a high-risk group for COVID19. To know about the frequency of comorbidities, signs and symptoms, the presence of lymphopenia, antibodies response to SARS-CoV2 and cytokine and chemokine serum concentration, six pregnant women with COVID19 were studied at the moment of admission. The lower concentration of CCL17 was detected in the Pregnant COVID19 group, similar concentration of IL-6 was also detected in non-pregnant and pregnant COVID19 patients. Our result show that pregnant and non-pregnant women with COVID19 has similar cytokine profile.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.